All In Biotech

Drug Trial Radar · NCT03781063

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Sep 20, 2019

Primary completion

May 8, 2025

Study completion May 8, 2025

Sponsor

Lead sponsor
Sermonix Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
Linical Accelovance Group
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor. The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The secondary objectives are to evaluate: 1. Clinical benefit rate (CBR) and Objective Response Rate (ORR) 2. Duration of response 3. Time to response 4. Overall Survival (OS) 5. Pharmacokinetics of lasofoxifene 6. Quality of life (QoL): Quality of Life (QoL): vaginal assessment scale (VAS) and vulvar assessment scale (VuAS) questionnaires 7. Safety of lasofoxifene 8. Response to various ESR1 mutation (Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N).

Conditions

  • Locally Advanced or Metastatic Breast Cancer

Interventions

  • LasofoxifeneDrug

    Estrogen receptor antagonist antineoplastic agent

  • FulvestrantDrug

    Estrogen receptor antagonist antineoplastic agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: through study completion, an average of 1 year

Locations

51 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Yuma Regional Medical Center (JIT)

    Yuma, Arizona

  • City of Hope Comprehensive Cancer

    Duarte, California

  • Compassionate Care Research Group

    Fountain Valley, California

  • UCSF Cancer Center

    San Francisco, California

  • Rocky Mountain Cancer Centers

    Longmont, Colorado

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Miami Cancer Institute

    Miami, Florida

  • Ocala Oncology Center (JIT)

    Oscala, Florida

  • Florida Cancer Specialists

    Tallahassee, Florida

  • The Bond Clinic Cancer & Research Center.

    Winter Haven, Florida

  • Emory University

    Atlanta, Georgia

  • Hawaii Cancer Care (JIT)

    Honolulu, Hawaii

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Illinois Cancer Care (JIT)

    Peoria, Illinois

  • Carle Cancer Center

    Urbana, Illinois

  • Beacon Health (JIT)

    South Bend, Indiana

  • University of Louisville / James Graham Brown Cancer Center

    Louisville, Kentucky

  • FMH James M Stockman Cancer Institute (JIT)

    Frederick, Maryland

  • Mayo Clinic

    Rochester, Minnesota

  • Hattiesburg Clinic Hematology/Oncology

    Hattiesburg, Mississippi

  • Saint Luke's Cancer Institute

    Kansas City, Missouri

  • HCA Midwest Health

    Kansas City, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Comprehensive Cancer Centers of Nevada (JIT)

    Las Vegas, Nevada

  • New Jersey Cancer Care and Blood Disorders (JIT)

    Belleville, New Jersey

  • Summit Medical Group (JIT)

    Florham Park, New Jersey

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Duke University Medical Center

    Durham, North Carolina

  • TriHealth Cancer Institute

    Cincinnati, Ohio

  • The Ohio State University - Comprehensive Cancer Center

    Columbus, Ohio

  • Ohio Health (JIT)

    Columbus, Ohio

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Sanford Cancer Center (JIT)

    Sioux Falls, South Dakota

  • Tennessee Oncology Chattanooga

    Chattanooga, Tennessee

  • West Cancer Center

    Germantown, Tennessee

  • Tennessee Oncology/SCRI

    Nashville, Tennessee

  • Mary Crowley Cancer Research (JIT)

    Dallas, Texas

  • Oncology Consultants (JIT)

    Houston, Texas

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.